person · Reporting owner

PYOTT DAVID E I

Disclosed activity across 5 companies

Tapewire entity: 34936
SEC CIK: 0001051578

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	June 01, 2026	June 03, 2026
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	May 21, 2024	May 23, 2024
PLIANT THERAPEUTICS, INC.PLRX · Entity 7022	Director	June 05, 2025	June 10, 2025
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836	Director	September 15, 2026	September 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,582	Ending reported balance After 2026-06-01 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2026-06-01 · Exercise / conversion · Acquired 3,830 · Balance 5,412 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. Row 2 · 2026-06-01 · Sale · Disposed 921 · Balance 4,491 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-06-01 · Sale · Disposed 1,175 · Balance 3,316 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-06-01 · Sale · Disposed 1,222 · Balance 2,094 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-06-01 · Sale · Disposed 495 · Balance 1,599 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-06-01 · Sale · Disposed 17 · Balance 1,582 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.20 · Expires 2026-06-03	Direct	0	Reported balance After 2026-06-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-06-01 · Exercise / conversion · Disposed 3,830 · Balance 0 F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026. F7: This stock option was fully vested and exercisable as of June 3, 2017.
Common StockSEC Table I · non-derivative	Indirectby Trust	27,900	Reported balance Holding disclosure · report date 2026-06-01 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 27,900 F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.

F7: This stock option was fully vested and exercisable as of June 3, 2017.

BIOMARIN PHARMACEUTICAL INC

Report date May 21, 2024 · Filed May 23, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	49,750	Reported balance After 2024-05-21 transaction · row 1 1 source row Row 1 · 2024-05-21 · Grant · Acquired 4,720 · Balance 49,750 F1: Restricted stock units granted on May 21, 2024. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on May 21, 2024. Price not applicable.

PLIANT THERAPEUTICS, INC.

Report date June 05, 2025 · Filed June 10, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2035-06-05	Direct	30,000	Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Tarsus Pharmaceuticals, Inc.

Report date September 15, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy the David E.I. Pyott Trust	9,575	Reported balance After 2026-09-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 9,575 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	605	Reported balance After 2026-09-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605 F3: Each RSU represents a contingent right to receive one share of the Company's common stock. F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

F3: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avery Dennison Corp

Report date April 23, 2020 · Filed April 24, 2020

Section 16 reporting ended · disclosed 2020-04-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,684	Reported balance After 2020-04-23 transaction · row 1 1 source row Row 1 · 2020-04-23 · Exercise / conversion · Acquired 1,414 · Balance 18,684
2019 Director RSU AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-05-01	Direct	0	Reported balance After 2020-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-04-23 · Exercise / conversion · Disposed 1,414 · Balance 0 F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected.
Common Stock Units - DDECPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 1988-08-08	IndirectDDECP	52,267.5096	Reported balance Holding disclosure · report date 2020-04-23 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 52,267.5096

Filing footnotes · ownership attribution and instrument terms

F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 31, 2020 Filed Sep 2, 2020 01:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	PurchaseCommon Stock	900	$78.84	$70,955.37	Disclosure SEC source: 0001567619-20-016270 · doc1.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,740 F2 · price: The price in column 4 is the weighted average price. The actual purchase price paid ranged from $78.78 to $78.91. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price. Read SEC document
August 31, 2020 Filed Sep 2, 2020 01:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	PurchaseCommon Stock	11,900	$78.22	$930,759.69	Disclosure SEC source: 0001567619-20-016270 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,840 F1 · price: The price in column 4 is the weighted average price. The actual purchase price paid ranged from $77.78 to $78.76. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:49 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	4,581	$0.00 Strike: $148.77	$0.00	Disclosure SEC source: 0001735276-20-000074 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 4,581 shares Expires 2030-07-01 Read SEC document
May 27, 2020 Filed May 29, 2020 22:32 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,300	$0.00	$0.00	Disclosure SEC source: 0001567619-20-011373 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,940 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document
April 23, 2020 Filed Apr 24, 2020 20:26 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2019 Director RSU Award · Derivative	1,414	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-20-014435 · form4.xml · derivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,414 shares Expires 2020-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected. Read SEC document
April 23, 2020 Filed Apr 24, 2020 20:26 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	1,414	$107.56	$152,089.84	Disclosure SEC source: 0001127602-20-014435 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2020 Filed Feb 5, 2020 20:04 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2010 Director Stock Option · Derivative	5,027	$0.00 Strike: $38.18	$0.00	Disclosure SEC source: 0001127602-20-003727 · form4.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,027 shares Expires 2020-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options are exercisable in three cumulative installments of 33% each year beginning on the first anniversary date of the grant, which is the date given . Read SEC document
February 03, 2020 Filed Feb 5, 2020 20:04 UTC	Avery Dennison Corp AVY · Entity 3410	SaleCommon Stock	5,027	$132.72	$667,183.44	Disclosure SEC source: 0001127602-20-003727 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,270 F1 · price: This transaction was executed in multiple trades at prices ranging from $132.67 to $132.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 03, 2020 Filed Feb 5, 2020 20:04 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	5,027	$38.18	$191,930.86	Disclosure SEC source: 0001127602-20-003727 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 01, 2019 Filed Jul 2, 2019 20:06 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $72.01	$0.00	Disclosure SEC source: 0001735276-19-000063 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-30 Read SEC document
June 04, 2019 Filed Jun 6, 2019 21:47 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,430	$0.00	$0.00	Disclosure SEC source: 0001567619-19-012958 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,640 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document
May 01, 2019 Filed May 2, 2019 23:38 UTC	Avery Dennison Corp AVY · Entity 3410	Grant2019 Director RSU Award · Derivative	1,414	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-017138 · form4.xml · derivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,414 Underlying: Common Stock · 1,414 shares Expires 2020-05-01 F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Avery Dennison Corporation common stock. Read SEC document
May 01, 2019 Filed May 2, 2019 23:38 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2018 Director RSU Award · Derivative	1,336	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-017138 · form4.xml · derivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,336 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2019 Filed May 2, 2019 23:38 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2016 Director RSU Award · Derivative	641	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-19-017138 · form4.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 641 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares reflect the vesting of the third tranche of restricted stock units granted on May 1, 2016. Read SEC document
May 01, 2019 Filed May 2, 2019 23:38 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	1,336	$109.63	$146,465.68	Disclosure SEC source: 0001127602-19-017138 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2019 Filed May 2, 2019 23:38 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	641	$109.63	$70,272.83	Disclosure SEC source: 0001127602-19-017138 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 27, 2018 Filed Nov 28, 2018 22:01 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2009 Director Stock Option · Derivative	2,000	$0.00 Strike: $20.64	$0.00	Disclosure SEC source: 0001127602-18-034613 · form4.xml · derivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2019-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Option grant under the Avery Dennison Corporation Director Equity Plan, as amended and restated. Options are exercisable in two cumulative installments of 50% each year beginning on the first anniversary date of the grant, which is the date given. Read SEC document
November 27, 2018 Filed Nov 28, 2018 22:01 UTC	Avery Dennison Corp AVY · Entity 3410	SaleCommon Stock	2,000	$93.00	$186,000.00	Disclosure SEC source: 0001127602-18-034613 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,293 Read SEC document
November 27, 2018 Filed Nov 28, 2018 22:01 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	2,000	$20.64	$41,280.00	Disclosure SEC source: 0001127602-18-034613 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2018 Filed Jun 22, 2018 20:19 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $105.26	$0.00	Disclosure SEC source: 0001735276-18-000031 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2028-06-19 Read SEC document
June 05, 2018 Filed Jun 8, 2018 01:13 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,300	$0.00	$0.00	Disclosure SEC source: 0001140361-18-027799 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,210 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Grant2018 Director RSU Award · Derivative	1,336	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-016057 · form4.xml · derivative · entry 7 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336 Underlying: Common Stock · 1,336 shares Expires 2019-05-01 F3 · shares: The restricted stock units vest on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of Avery Dennison Corporation common stock. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2017 Director RSU Award · Derivative	1,678	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-016057 · form4.xml · derivative · entry 6 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,678 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2016 Director RSU Award · Derivative	641	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-016057 · form4.xml · derivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 641 Underlying: Common Stock · 641 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares reflect the vesting of the second tranche of restricted stock units granted on May 1, 2016. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2015 Director RSU Award · Derivative	747	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-016057 · form4.xml · derivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 747 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares reflect the vesting of the third tranche of restricted stock units granted on May 1, 2015. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	1,678	$104.80	$175,854.40	Disclosure SEC source: 0001127602-18-016057 · form4.xml · nonDerivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	641	$104.80	$67,176.80	Disclosure SEC source: 0001127602-18-016057 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2018 Filed May 2, 2018 22:05 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	747	$104.80	$78,285.60	Disclosure SEC source: 0001127602-18-016057 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 30, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2008 Director Stock Option · Derivative	1,702	$0.00 Strike: $52.12	$0.00	Disclosure SEC source: 0001127602-17-026731 · form4.xml · derivative · entry 6 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,702 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 30, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	SaleCommon Stock	1,702	$94.00	$159,988.00	Disclosure SEC source: 0001127602-17-026731 · form4.xml · nonDerivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,303 Read SEC document
August 30, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	1,702	$52.12	$88,699.73	Disclosure SEC source: 0001127602-17-026731 · form4.xml · nonDerivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 28, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2008 Director Stock Option · Derivative	298	$0.00 Strike: $52.12	$0.00	Disclosure SEC source: 0001127602-17-026731 · form4.xml · derivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,702 Underlying: Common Stock · 298 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 28, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	SaleCommon Stock	298	$94.00	$28,012.00	Disclosure SEC source: 0001127602-17-026731 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,303 Read SEC document
August 28, 2017 Filed Aug 30, 2017 22:02 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	298	$52.12	$15,530.27	Disclosure SEC source: 0001127602-17-026731 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:31 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantStock Option (right to buy) Common Stock · Derivative	4,910	$0.00 Strike: $89.60	$0.00	Disclosure SEC source: 0001140361-17-024512 · doc1.xml · derivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:31 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	2,050	$0.00	$0.00	Disclosure SEC source: 0001140361-17-024512 · doc1.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document
June 02, 2017 Filed Jun 6, 2017 20:59 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	11,250	$0.00 Strike: $71.99	$0.00	Disclosure SEC source: 0001553878-17-000028 · edgardoc.xml · derivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-06-01 Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Grant2017 Director RSU Award · Derivative	1,678	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-016576 · form4.xml · derivative · entry 7 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,678 Underlying: Common Stock · 1,678 shares Expires 2018-05-01 F4 · shares: The restricted stock units vest on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of Avery Dennison Corporation common stock. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2016 Director RSU Award · Derivative	640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-016576 · form4.xml · derivative · entry 6 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282 Underlying: Common Stock · 640 shares Expires 2019-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares reflect the vesting of the first tranche of restricted stock units granted on May 1, 2016. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2015 Director RSU Award · Derivative	746	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-016576 · form4.xml · derivative · entry 5 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747 Underlying: Common Stock · 746 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares reflect the vesting of the second tranche of restricted stock units granted on May 1, 2015. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversion2014 Director RSU Award · Derivative	859	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-016576 · form4.xml · derivative · entry 4 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 859 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares reflect the vesting of the third tranche of restricted stock units granted on May 1, 2014. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	640	$83.42	$53,388.80	Disclosure SEC source: 0001127602-17-016576 · form4.xml · nonDerivative · entry 3 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	746	$83.42	$62,231.32	Disclosure SEC source: 0001127602-17-016576 · form4.xml · nonDerivative · entry 2 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 01, 2017 Filed May 3, 2017 19:08 UTC	Avery Dennison Corp AVY · Entity 3410	Exercise / conversionCommon Stock	859	$83.42	$71,657.78	Disclosure SEC source: 0001127602-17-016576 · form4.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 13, 2016 Filed Oct 14, 2016 20:22 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	PurchaseCommon Stock	27,900	$37.00	$1,032,327.90	Disclosure SEC source: 0001553878-16-000059 · edgardoc.xml · nonDerivative · entry 1 PYOTT DAVID E I · CIK 0001051578 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 27,900 F1 · ownership.nature: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.